No wisepilot, no matter how great his talent and experience, fails to use his checklist.
– Charlie Munger
On June 25, 2018, the FDA made the historic approval of cannabidiol (Epidiolex) of GW Pharmaceuticals (NASDAQ:GWPH) for the treatment of seizure associated with Lennox-Gastaut syndrome and Dravet syndrome. The aforesaid catalyst is unprecedented, as it’s the first approval for a cannabis-derived product as a legitimate medication. Despite the approval, the stock does not trade higher subsequent to the mentioned event. Interestingly, the approval caused investors to “sell on the news.” Be that as it
Get Real-Time Updates from The Daily Marijuana Observer
